GATEACRE BROW SURGERY
1 GATEACRE BROW, LIVERPOOL
HF 4
The percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE inhibitor or Angiotensin Receptor Blocker, who are additionally treated with a beta-blocker licensed for heart failure, or recorded as intolerant to or having a contraindication to beta-blockers.
| Indicator | Year | Numerator | Denominator | Ratio | Centile |
|---|---|---|---|---|---|
| HF 4 | 2010 | 22 | 28 | 78.6% | |
| HF 4 | 2011 | 24 | 31 | 77.4% | |
| HF 4 | 2012 | 31 | 40 | 77.5% | |
| HF 4 | 2013 | 31 | 36 | 86.1% | |
| HF004 | 2014 | 21 | 21 | 100.0% | |
| HF004 | 2015 | 20 | 22 | 90.9% | |
| HF004 | 2016 | 18 | 18 | 100.0% | |
| HF004 | 2017 | 36 | 38 | 94.7% | |
| HF004 | 2018 | 34 | 35 | 97.1% | |
| HF004 | 2019 | 36 | 38 | 94.7% | |
| HF004 | 2020 | 29 | 29 | 100.0% | |
| HF006 | 2021 | 35 | 37 | 94.6% | |
| HF006 | 2022 | 36 | 36 | 100.0% | |
| HF006 | 2023 | 36 | 36 | 100.0% |
